

Renal tumours: Locally advanced and metastatic disease

Poster Session 22

Saturday 10 July
17:00 - 18:00

Location Virtual Room 8
Chairs To be confirmed
M. Oya, Tokyo (JP)

We encourage you to view the abstracts prior to the session:

- On 8 June abstract bodies will be available for EAU members in the EAU21 Resource Centre.
- On 1 July abstract bodies and 5-minute explanatory presentations will be available for all delegates on the EAU21 Congress platform.

The presentations in this poster session (1 minute in length) are divided into groups, followed by discussion time to address questions from the audience and the chairpersons.

Learning objectives

Learning cutting edges of the subjects below:

- Surgeries for RCC with IVC thrombus
- Variant histology of RCC and angiomyolipoma including sarcomatoid variant and epithelioid angiomyolipoma
- Genetic testing of RCC and TSC
- Managing adverse events for patients treated with targeted agents or immune-checkpoint inhibitors
- Novel biomarkers for metastatic RCC
- Role of cytoreductive nephrectomy in the era of targeted agents and immunotherapy.

17:00 - 17:01

Introduction

17:01 - 17:15

Surgical aspects of advanced kidney tumors

P0623

Renal functional outcomes at 5 years from radical and partial nephrectomies in normal renal function patients: An untold story of hyperfiltrations
F. Trevisani, Milan (IT)

P0624

Prostate Specific Membrane Antigen (PSMA) PET/CT compared to standard of care imaging in the assessment of renal cancers: A multi-institutional series
A. Tariq, Windsor (AU)

P0625

Robot-assisted radical nephrectomy and inferior vena cava level I-III thrombectomy: An update on perioperative and mid-term oncologic outcomes from a tertiary-referral centre
U. Anceschi, Rome (IT)

P0626

Survival analysis of Renal Cell Carcinoma with venous tumor thrombus: A single centre 20-yr experience
M.L. Righetto, Padova (IT)

P0627

Predictive factors of recurrence after surgery in patients with non-metastatic renal cell carcinoma with venous tumor thrombus (uroccr-56 study) and the impact of adjuvant treatment
M. Baboudjian, Marseille (FR)

P0628

Radical nephrectomy and caval thrombectomy with heart beating technique for renal cell cancer with tumor thrombus extension into inferior vena cava and right atrium: A less invasive multidisciplinary approach
S. Guzzo, Vanzago (IT)

17:07 - 17:15

Discussion

17:15 - 17:31

Impact of variant histology

P0629

Cognitive function after cardiopulmonary bypass and deep hypothermic circulatory arrest in the management of renal cell carcinoma with IVC tumor thrombus

J. Huang, Shanghai (CN)

P0630

The natural history of sarcomatoid renal-cell carcinoma, a stage-by-stage analysis

K.H. Tully, Herne (DE)

P0631

Methylthioadenosine Phosphorylase (MTAP) deletion is more common in Sarcomatoid (srcRCC) than in clear cell Renal Cell Carcinoma (ccRCC)

A. Necchi, Milan (IT)

P0632

Construction and validation of a robust genomic classifier for high-risk sporadic type 2 papillary renal cell carcinoma: support more accurate utilization of mTOR inhibitors

X. Tian, Shanghai (CN)

P0633

Papillary renal cell carcinoma type I and II: Two distinct diseases with different clinical and therapeutical implications

G. Rosiello, Bacoli (IT)

P0634

Evaluation of clinicopathological profiles and development of a risk model in epithelioid angiomyolipoma patients: A large-scale Chinese retrospective study

A. Anwaier, Shanghai (CN)

P0635

A familial TSC1 exon 5 microdeletion associated with angioliopomas and renal-cell carcinoma: A mTORopathy Tunisian familial pedigree

B. Abdelmoula, Sfax (TN)

P0636

External validation of the VHL alliance guidelines for VHL genetic testing in patients diagnosed with renal cell carcinoma

A. Larcher, Milan (IT)

17:23 - 17:31

Discussion

17:31 - 17:55

Metastatic disease, role of cytoreductive nephrectomy

P0637

Does the time before starting first-line treatment influences the survival of patients with metastatic renal cell cancer in favorable-risk groups?

C. Rolley, Angers (FR)

P0638

Overall Adverse events of drugs for metastatic renal cell carcinoma: Real world reporting patterns from eudra vigilance database

C. De Nunzio, Rome (IT)

P0639

Severe immune-related adverse events in nivolumab-treated patients with metastatic RCC are associated to PDCD1 polymorphism

K. Numakura, Akita (JP)

P0640

Renal mass size and presence of synchronous lung metastasis at time of diagnosis: Implications for chest imaging

M. Jamil, Detroit (US)

P0641

Evaluation of a panel of preoperative blood-based systemic inflammatory response biomarkers for outcome prediction in patients treated with cytoreductive nephrectomy for metastatic renal cell carcinoma

E. Laukhtina, Moscow (RU)

P0642

Prognostic significance of radiologic infiltrative feature of primary renal tumor in metastatic renal cell carcinoma

H. Tanaka, Tokyo (JP)

- P0643** **Is presence of vena caval thrombosis in primary tumor associated with worsened outcomes in metastatic renal cell carcinoma: Analysis of the REMARCC registry**
M.F. Meagher, La Jolla (US)
- P0644** **Optimizing patient selection for deferred cytoreductive nephrectomy in the contemporary era of targeted therapy**
J. Choy, London (GB)
- P0645** **The role of cytoreductive nephrectomy for metastatic renal cell carcinoma in National Health Insurance Service**
J. Gook, Seoul (KR)
- P0646** **Cytoreductive nephrectomy in patients receiving TKI therapy versus immune checkpoint inhibitor therapy: Comparative outcome analysis of the REMARCC registry**
M.F. Meagher, La Jolla (US)
- P0647** **Nephrectomy after complete response to immune checkpoint inhibitors for Metastatic Renal Cell Carcinoma (mRCC): A surgical challenge allowing favorable oncological outcomes**
G. Pignot, Marseille (FR)
- P0648** **Predictors of complications after cytoreductive nephrectomy in the immunotherapy era: Results from a multicenter international study**
M. Marchioni, Cantalice (RI) (IT)
- P0649** **Surgical safety of Cytoreductive Nephrectomy (CN) following pretreatment with Immune Checkpoint Inhibition (ICI) combination therapy in primary metastatic clear-cell Renal Carcinoma (mccRCC)**
N.M. Graafland, Amsterdam (NL)
- P0650** **Prognostic effect of preoperative serum albumin to globulin ratio in patients treated with cytoreductive nephrectomy for metastatic renal cell carcinoma**
E. Laukhtina, Moscow (RU)
- P0651** **Management of local recurrence after radical nephrectomy: Surgical removal is still the gold standard. Results from a multicenter international cohort**
M. Marchioni, Cantalice (RI) (IT)
- P0652** **Urine free glycosaminoglycans as monitoring biomarkers in confined renal cell carcinoma - A prospective observational study**
F. Gatto, Solna (SE)
- 17:47 - 17:55** **Discussion**
-
- 17:55 - 18:00** **Expert summary**
U. Capitanio, Milan (IT)